![Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus | Circulation Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus | Circulation](https://www.ahajournals.org/cms/asset/ca8ed6a3-f4d6-4e21-80dd-7a07f40e42d8/1571fig03.gif)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus | Circulation
![Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places](https://www.researchgate.net/profile/Verena-Lieb-Geb-Huppert/publication/362657324/figure/tbl4/AS:11431281078886514@1660321290661/Invasive-carcinoma-compared-to-normal-tissue_Q320.jpg)
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
![A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes](https://www.ahajournals.org/cms/asset/4532f03f-ba34-487b-8ae4-4239307d5e49/hcq0031102820004.jpg)
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes
![Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation](https://www.ahajournals.org/cms/asset/1367db44-0ff7-4fa5-9db1-87b944efe4a2/circulationaha.120.049447.fig04.gif)
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
![Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use | Circulation Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use | Circulation](https://www.ahajournals.org/cms/asset/a2402b9a-1e2f-4234-bca7-1fb63aabf7a9/1605fig01.gif)
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use | Circulation
![Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places](https://www.researchgate.net/publication/357109227/figure/fig1/AS:1101829383434240@1639708004715/Overview-of-all-57-separated-oral-anticancer-drugs-Combined-representation-of-individual_Q320.jpg)
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
![Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/356edc13-d52a-43ac-8487-47af51c0819d/3058fig01.jpg)
Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
![Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/f02f3af4-eb03-4873-997f-788e1fc6f725/3058fig02.jpg)
Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
![Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation](https://www.ahajournals.org/cms/asset/684a4e65-b854-4e68-9f8f-216449fb57fc/circulationaha.120.049447.fig02.gif)
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
![The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation](https://www.ahajournals.org/cms/asset/e256971a-6465-4e92-8bc0-97d661b55f3a/circulationaha.120.046397.fig01.gif)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
![Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome | Circulation Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome | Circulation](https://www.ahajournals.org/cms/asset/6e589937-2e39-4074-bd92-6abaa43184cf/circulationaha.120.046524.fig01.gif)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome | Circulation
![The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation](https://www.ahajournals.org/cms/asset/dd2d61b4-e1fa-4431-8ca3-436f55b22251/circulationaha.120.046397.fig04.gif)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
![Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes | Arteriosclerosis, Thrombosis, and Vascular Biology Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/cadee75e-bafe-4b7e-ae4c-23d556dbe6b0/25ff2.jpg)